marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
ADMA Biologics Balance Sheet 2011-2024 | ADMA
Annual Balance Sheet ADMA Biologics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-40.5 M | -74.9 M | -43 M | 37.4 M | 58 M | 21.5 M | -137 K | 10.3 M | 5.29 M | -16.8 M | -21.1 M | -8.57 M | 9.81 M |
Long Term Debt |
9.78 M | 10.7 M | 7.46 M | 93 M | 83.2 M | 44.1 M | 43 M | 14.1 M | 15.7 M | 9.67 M | 5 M | 3.88 M | - |
Long Term Debt Current |
1.04 M | 905 K | 591 K | 366 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 99.5 M | 86.9 M | 59.5 M | 58.2 M | 16.9 M | 18.7 M | 11.4 M | 6.75 M | 4.31 M | - |
Total Current Liabilities |
49.8 M | 39.3 M | 30.4 M | 19.9 M | 14 M | 9.63 M | 9.44 M | 11.2 M | 4.22 M | 4.2 M | 3.66 M | 1.82 M | - |
Total Liabilities |
194 M | 196 M | 135 M | 119 M | 101 M | 69.1 M | 67.7 M | 28.1 M | 22.9 M | 16 M | 10.4 M | 6.13 M | 9.82 K |
Deferred Revenue |
182 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 145 K | 145 K | - | 75.6 K | - | - |
Retained Earnings |
-506 M | -478 M | -412 M | -340 M | -265 M | -216 M | -151 M | -107 M | -87.4 M | -58.5 M | -52.6 M | -37.1 M | -140 K |
Total Assets |
329 M | 348 M | 276 M | 208 M | 127 M | 88.9 M | 108 M | 23.7 M | 23.7 M | 32 M | 32 M | 15.6 M | 8.51 K |
Cash and Cash Equivalents |
51.4 M | 86.5 M | 51.1 M | 55.9 M | 26.8 M | 22.8 M | 43.1 M | 9.91 M | 10.4 M | 17.2 M | 26.1 M | 12.5 M | 87.8 K |
Book Value |
135 M | 152 M | 141 M | 88.2 M | 26.2 M | 19.8 M | 40.3 M | -4.46 M | 821 K | 15.9 M | 21.6 M | 9.42 M | -1.31 K |
Total Shareholders Equity |
135 M | 152 M | 141 M | 88.2 M | 26.2 M | 19.8 M | 40.3 M | -4.46 M | 821 K | 6.01 M | 21.6 M | 9.42 M | - |
All numbers in USD currency
Quarterly Balance Sheet ADMA Biologics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
8.86 M | 9.18 M | 9.49 M | 9.78 M | 9.97 M | 10.2 M | 10.5 M | 10.7 M | 10.6 M | 10.9 M | 7.28 M | 7.46 M | 6.92 M | 7.07 M | - | 4.33 M | 4.33 M | 4.33 M | - | - | - | - | - | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 1.79 M | 1.79 M | 1.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
159 M | 188 M | 197 M | 194 M | 198 M | 196 M | 195 M | 196 M | 200 M | 183 M | 181 M | 135 M | 136 M | 121 M | 123 M | 119 M | 119 M | 119 M | 119 M | 101 M | 101 M | 101 M | 101 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 67.7 M | 67.7 M | 67.7 M | 67.7 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 22.9 M | 22.9 M | 22.9 M | 22.9 M | 21 M | 21 M | 21 M | 21.2 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 6.13 M | 6.13 M | 6.13 M | 6.13 M | 2.54 M | 2.54 M | 2.54 M | 2.54 M |
Deferred Revenue |
143 K | 1.13 M | 1.12 M | 182 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | - | 143 K | 143 K | 143 K | - | 143 K | - | - | - | 143 K | - | - | - | 145 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-420 M | -456 M | -488 M | -506 M | -489 M | -491 M | -485 M | -478 M | -466 M | -451 M | -437 M | -412 M | -395 M | -378 M | -359 M | -340 M | -340 M | -340 M | -340 M | -265 M | -265 M | -265 M | -265 M | -216 M | -216 M | -216 M | -216 M | -151 M | -151 M | -151 M | -151 M | -107 M | -107 M | -107 M | -107 M | -87.4 M | -87.4 M | -87.4 M | -87.4 M | -69.4 M | -69.4 M | -69.4 M | -69.4 M | -52.6 M | -52.6 M | -52.6 M | -52.6 M | -37.1 M | -37.1 M | -37.1 M | -37.1 M | -29.8 M | -29.8 M | -29.8 M | -29.8 M |
Total Assets |
391 M | 376 M | 351 M | 329 M | 349 M | 343 M | 341 M | 348 M | 301 M | 297 M | 308 M | 276 M | 239 M | 233 M | 236 M | 208 M | 208 M | 208 M | 208 M | 127 M | 127 M | 143 M | 127 M | 88.9 M | 88.9 M | 88.9 M | 88.9 M | 108 M | 108 M | 108 M | 108 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 27 M | 27 M | 27 M | 27.2 M | 32 M | 32 M | 32 M | 32 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 2.93 M | 2.93 M | 2.93 M | 2.93 M |
Cash and Cash Equivalents |
86.7 M | 88.2 M | 45.3 M | 51.4 M | 74.2 M | 62.5 M | 69.2 M | 86.5 M | 34.9 M | 52.4 M | 69.5 M | 51.1 M | 34.4 M | 42.4 M | 62 M | 55.9 M | 55.9 M | 55.9 M | 55.9 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 22.8 M | 22.8 M | 22.8 M | 43.1 M | 43.1 M | 43.1 M | 43.1 M | 9.91 M | 9.91 M | 9.91 M | 9.91 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 26.1 M | 26.1 M | 26.1 M | 26.1 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 87.8 K | 87.8 K | 87.8 K | 87.8 K |
Book Value |
232 M | 188 M | 154 M | 135 M | 151 M | 147 M | 146 M | 152 M | 100 M | 114 M | 127 M | 141 M | 103 M | 112 M | 113 M | 88.2 M | 88.2 M | 88.2 M | 88.2 M | 26.2 M | 26.2 M | 42.4 M | 26.2 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | -4.46 M | -4.46 M | -4.46 M | -4.46 M | 821 K | 821 K | 821 K | 821 K | 6.01 M | 6.01 M | 6.01 M | 6.01 M | 21.6 M | 21.6 M | 21.6 M | 21.6 M | 9.42 M | 9.42 M | 9.42 M | 9.42 M | 386 K | 386 K | 386 K | 386 K |
Total Shareholders Equity |
232 M | 188 M | 154 M | 135 M | 151 M | 147 M | 146 M | 152 M | 100 M | 114 M | 127 M | 141 M | 103 M | 112 M | 113 M | 88.2 M | 88.2 M | 88.2 M | 88.2 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | -4.46 M | -4.46 M | -4.46 M | -4.46 M | 821 K | 821 K | 821 K | 821 K | 6.01 M | 6.01 M | 6.01 M | 6.01 M | 21.6 M | 21.6 M | 21.6 M | 21.6 M | 9.42 M | 9.42 M | 9.42 M | 9.42 M | 386 K | 386 K | 386 K | 386 K |
All numbers in USD currency